Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01299337 · ClinicalTrials.gov registry record
Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)
A clinical trial of Depression, sponsored by Mayo Clinic.
- Completed
- Registry status
- 29
- Enrollment target
- 1
- Study location
NCT01299337: Completed study of Depression, sponsored by Mayo Clinic.
NCT01299337 is a study of Depression that has completed, run by Mayo Clinic. The registered enrollment target is 29 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01299337, a study of Depression, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is: * To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy. * To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment. * To evaluate whether thyroid status at the time of remission is associated with subsequent relapse rate. * To evaluate genetic polymorphisms in enzymes responsible for thyroid metabolism and the serotonin transporter promoter gene in depression (5-HTTLRP).
Conditions Studied
Interventions
- DRUG T3
Study Locations (1)
Minnesota
- Mayo Clinic Department of Psychiatry and Psychology - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-04 |
What the finished NCT01299337 record still lists
NCT01299337 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 1 intervention - of which T3 is the first listed.
NCT01299337 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01299337 about?
NCT01299337 is a clinical study titled "Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)". The purpose of this study is: * To evaluate liothyronine (Cytomel) as an accelerating agent (i.e. faster rate to clinical remission) to electroconvulsive therapy. * To evaluate whether thyroid supplement acceleration can reduce the neurocognitive side effect of ECT treatment. * To evaluate whether ...
What is the current status of trial NCT01299337?
This trial is currently completed. The enrollment target is 29 participants. The study started on 2008-06. Estimated completion is 2012-04.
What conditions does trial NCT01299337 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT01299337?
The interventions under investigation include: T3 (DRUG).
Who is sponsoring clinical trial NCT01299337?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01299337 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01299337's enrollment target sits among peer trials
29 576th of 679 higher than 99 of 679 other Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reaching Out to Distressed Medical Residents, Fellows and Faculty
RECRUITING · NA
-
Depression and Driving
RECRUITING
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Sleep to Reduce Incident Depression Effectively in Peripartum
RECRUITING · Phase 2
-
PET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD)
RECRUITING · Phase 1
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
- NCT03531450 · 29 participants · NA
Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia